Physician profile
Arnold Seid
NPI 1457450033
$42,879.79
in general payments reported to CMS, 2019-2025
42 companies · $6,375 in 2025
The $6,375 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,577 · 2020: $4,224 · 2021: $5,963 · 2022: $6,537 · 2023: $7,036 · 2024: $5,168 · 2025: $6,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Honoraria: $805 · Education: $39.24 · Travel and Lodging: $25.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,709.37 |
| Honoraria | $805.00 |
| Education | $39.24 |
| Travel and Lodging | $25.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $5,738.49 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Horizon Therapeutics Plc | $4,198.64 | 2019-2023 | Krystexxa |
| Abbvie INC. | $3,868.32 | 2019-2025 | Linzess, Qulipta, Ubrelvy |
| Novo Nordisk INC | $2,909.76 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $2,836.28 | 2019-2025 | Krystexxa, Repatha, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $2,373.87 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,284.90 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $2,041.68 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Janssen Pharmaceuticals, INC | $1,671.55 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $1,587.61 | 2019-2022 | |
| Pfizer INC. | $1,518.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,413.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $1,033.96 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $1,003.00 | 2019-2025 | Verquvo, Steglatro, Januvia |
| Sanofi-Aventis U.S. LLC | $992.08 | 2019-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Seid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.